Everything published about Retatrutide: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 20 mg | from 2 200 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
Retatrutide combines GIP, GLP-1 and glucagon receptor activity in one molecule. This triple mechanism connects appetite control with glucose regulation and energy metabolism.
An investigational triple-receptor agonist in clinical development for obesity and related metabolic conditions.
A prominent next-generation metabolic peptide with a triple mechanism and substantial phase 2 weight-loss results.
In the phase 2 obesity trial, the 12 mg group achieved average weight reduction of 24.2% at 48 weeks, compared with 2.1% for placebo. Exploratory measures also showed improvements in blood pressure, lipids and glucose-related markers.
Phase 2 research schedule: Subcutaneous administration once weekly. Target-dose groups: 1, 4, 8 or 12 mg weekly. Higher-dose groups began at 2 or 4 mg, depending on the arm, with protocol-defined escalation. Duration: 48 weeks. These are separate clinical-trial groups, not one dose ladder. Phase 3 schedules start at 2 mg and use their own escalation steps.
Nausea, diarrhoea and vomiting were the most frequent effects, often during escalation. Dose-dependent heart-rate increases were also observed; longer-term follow-up continues.
Retatrutide adds glucagon-receptor activity to GIP and GLP-1 signalling. That third pathway makes it a distinct metabolic research approach; separate trials should not be treated as a direct comparison.
from 2 200 000 ₫ for 20 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.